Antibody (13)Cell Grade Beads (1)
Launched (14)
Rabbit (13)- (1)
- (14)
PE Labeled (2)APC Labeled (2)Biotin-labeled (3)AF555 Labeled (1)FITC Labeled (1)AF647 Labeled (1)- (1)AF488 Labeled (1)Unconjugated (1)HRP Labeled (1)
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| PRO-1107 | PRO-1107 | Phase 2 Clinical | ProfoundBio (Suzhou) Co Ltd | Solid tumours; Ovarian Neoplasms; Stomach Neoplasms; Esophageal Neoplasms; Triple Negative Breast Neoplasms; Carcinoma, Transitional Cell; Endometrial Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
| Cofetuzumab Pelidotin | PF-06647020; PF-6647020; PTK7-ADC; PF-06523435; PF-7020; hu-24; ABBV-647; Anti-PTK7 ADC; h6M24-vc0101 | Phase 1 Clinical | Abbvie Inc, Stemcentrx Inc | Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |

[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521
[North America]: 1 Innovation Way, Newark, DE 19711, USA
[Switzerland]: ACRObiosystems AG, c/o Zug Dammstrasse Centre AG, Dammstrasse 19, 6300 Zug Switzerland



